QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
Positive News Sentiment  
NASDAQ:UTHR

United Therapeutics - UTHR Earnings Date, Estimates & Call Transcripts

$221.66
+3.30 (+1.51%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$218.72
▼
$223.44
50-Day Range
$216.46
▼
$244.17
52-Week Range
$158.38
▼
$245.48
Volume
330,445 shs
Average Volume
464,501 shs
Market Capitalization
$10.09 billion
P/E Ratio
16.78
Dividend Yield
N/A
Price Target
$250.14

Earnings Summary

Upcoming
Earnings Date
Nov. 2Estimated
Actual EPS
(Aug. 3)
$2.41 Missed By -$1.69
Consensus EPS
(Aug. 3)
$4.10
Last Year's Q3 EPS
(8/4/2021)
$3.65
Read Call Transcript
Listen to Call
Latest SEC 10-Q Filing
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

UTHR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

UTHR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

United Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20222$2.84$3.27$3.06
Q2 20222$4.15$4.35$4.25
Q3 20222$4.17$4.45$4.31
Q4 20222$3.83$3.91$3.87
FY 20228$14.99$15.98$15.49
Q1 20231$4.30$4.30$4.30
Q2 20231$5.41$5.41$5.41
Q3 20231$5.54$5.54$5.54
Q4 20231$5.44$5.44$5.44
FY 20234$20.69$20.69$20.69

UTHR Earnings Date and Information

United Therapeutics last announced its quarterly earnings data on August 3rd, 2022. The biotechnology company reported $2.41 EPS for the quarter, missing the consensus estimate of $4.10 by $1.69. The business had revenue of $466.90 million for the quarter, compared to analysts' expectations of $461.06 million. Its quarterly revenue was up 4.6% compared to the same quarter last year. United Therapeutics has generated $13.21 earnings per share over the last year ($13.21 diluted earnings per share) and currently has a price-to-earnings ratio of 16.8. Earnings for United Therapeutics are expected to grow by 15.98% in the coming year, from $15.21 to $17.64 per share. United Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 2nd, 2022 based off prior year's report dates.

United Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/2/2022
(Estimated)		        
8/3/2022Q2$4.10$2.41($1.69)$461.06 million$466.90 million      
5/4/2022Q1 2022$2.96$5.03+$2.07$5.03$420.02 million$461.90 million      
2/24/2022Q4 2021$3.77$2.35($1.42)$2.35$427.59 million$415.20 million    
11/3/20219/30/2021$3.37$3.42+$0.05$3.42$421.45 million$444.70 million    
8/4/20216/30/2021$3.02$3.65+$0.63$3.65$378.54 million$446.50 million      
5/5/20213/31/2021$2.60$0.61($1.99)$0.61$368.31 million$379.10 million    
2/23/202112/31/2020$2.96$2.19($0.77)$2.19$362.04 million$384.90 million    
10/28/20209/30/2020$2.41$3.84+$1.43$3.84$357.95 million$380.10 million    
7/29/20206/30/2020$2.41$2.41$2.41$339.97 million$362.00 million    
4/29/20203/31/2020$2.43$3.12+$0.69$3.12$343.68 million$356.30 million  
2/26/2020Q4 2019$2.47$1.20($1.27)$1.20$357.14 million$311.10 million  
10/30/2019Q3 2019$2.34$3.16+$0.82$3.01$342.28 million$401.50 million  
7/31/2019Q2 2019$2.40$4.66+$2.26$4.66$331.78 million$373.60 million
5/1/20193/31/2019$2.64($11.32)($13.96)($11.32)$335.72 million$362.70 million
2/27/2019Q4 2018$2.20$1.48($0.72)$1.48$355.81 million$381.40 million  
10/31/20189/30/2018$3.23$2.42($0.81)$2.42$378.22 million$412.70 million
8/1/2018Q2 2018$2.57$3.98+$1.41$3.98$368.63 million$444.50 million
5/2/2018Q1 2018$3.6170$5.57+$1.9530$5.57$393.96 million$389.20 million
2/21/2018Q4 2017$3.59$3.89+$0.30$3.69$420.55 million$464.70 million
10/25/2017Q3 2017$4.01$6.27+$2.26$6.27$426.43 million$445.50 million
7/27/2017Q2 2017$3.61($1.25)($4.86)($1.25)$391.53 million$444.60 million
4/26/2017Q1 2017$3.1250$3.89+$0.7650$3.89$399.59 million$370.50 million
2/22/2017Q4 2016$3.62$2.43($1.19)$2.43$415.51 million$409.00 million  
10/27/2016Q3 2016$3.47$3.50+$0.03$3.50$400.58 million$408.20 million  
7/28/2016Q2 2016$3.26$4.39+$1.13$4.39$395.15 million$412.60 million  
4/28/2016Q1 2016$3.33$4.84+$1.51$4.84$395.02 million$369.00 million  
2/25/2016Q4 2015$2.57$2.10($0.47)$2.10$388.29 million$404.90 million  
10/27/2015Q3 2015$2.44$5.02+$2.58$0.80$363.51 million$386.20 million  
7/28/2015Q2 2015$2.26$2.02($0.24)$2.13$360.41 million$347.20 million  
4/28/2015Q1 2015$2.10($0.22)($2.32)($0.08)$353.50 million$327.60 million
2/24/2015Q4 2014$2.19$2.17($0.02)$2.17$336.22 million$346.40 million
10/28/2014Q3 2014$1.84($0.53)($2.37)($0.53)$335.10 million$330.00 million
7/29/2014Q2 2014$1.66$2.10+$0.44$2.10$308.04 million$322.80 million
4/29/2014Q1 2014$1.57$2.64+$1.07$2.85$300.14 million$289.40 million  
2/25/2014Q4 2013$1.69($0.60)($2.29)($0.60)$295.43 million$289.02 million  
10/29/2013Q3 2013$1.60$1.17($0.43)$1.17$279.02 million$302.20 million  
7/25/2013Q2 2013$1.47$1.52+$0.05$1.52$250.17 million$280.60 million
4/25/2013Q1 2013$1.47$1.19($0.28)$1.19$241.14 million$245.14 million  
2/26/2013Q4 2012$1.25$1.65+$0.40$233.41 million$243.82 million
11/1/2012Q312$1.26$2.82+$1.56$227.63 million$242.50 million
7/26/2012$1.23$1.34+$0.11  
4/26/2012$1.00$1.32+$0.32
2/14/2012$0.85$0.77($0.08)  
10/27/2011$0.88$1.32+$0.44
7/28/2011$0.49$1.27+$0.78
4/28/2011$0.64$1.29+$0.65  
2/15/2011$0.62$0.15($0.47)
10/28/2010Q3 2010$0.54$0.66+$0.12$0.66
7/28/2010Q2 2010$0.45$0.62+$0.17$0.62
4/29/2010Q1 2010$0.30$0.32+$0.02$0.32
2/16/2010Q4 2009$0.28$0.16($0.12)$0.38
10/29/2009Q3 2009$0.34$0.21($0.13)$0.21
7/31/2009Q2 2009$0.28($0.05)($0.33)($0.05)
5/1/2009Q1 2009$0.31$0.24($0.07)$0.24
2/17/2009Q4 2008$0.26$0.43+$0.17$2.57
10/30/2008Q3 2008$0.30$0.25($0.05)$0.25
7/31/2008Q2 2008$0.30$0.29($0.01)$0.29
5/1/2008Q1 2008$0.27$0.24($0.03)$0.24
2/19/2008Q4 2007$0.25$0.04($0.21)$0.04












United Therapeutics Earnings - Frequently Asked Questions

When is United Therapeutics's earnings date?

United Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 2nd, 2022 based off last year's report dates. Learn more on UTHR's earnings history.

Did United Therapeutics beat their earnings estimates last quarter?

In the previous quarter, United Therapeutics (NASDAQ:UTHR) missed the analysts' consensus estimate of $4.10 by $1.69 with a reported earnings per share (EPS) of $2.41. Learn more on analysts' earnings estimate vs. UTHR's actual earnings.

How can I listen to United Therapeutics's earnings conference call?

The conference call for United Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read United Therapeutics's conference call transcript?

The conference call transcript for United Therapeutics's latest earnings report can be read online. Read Transcript

How can I view United Therapeutics's earnings report?

United Therapeutics's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does United Therapeutics generate each year?

United Therapeutics (NASDAQ:UTHR) has a recorded annual revenue of $1.69 billion.

How much profit does United Therapeutics generate each year?

United Therapeutics (NASDAQ:UTHR) has a recorded net income of $475.80 million. UTHR has generated $13.21 earnings per share over the last four quarters.

What is United Therapeutics's price-to-earnings ratio?

United Therapeutics (NASDAQ:UTHR) has a trailing price-to-earnings ratio of 16.78 and a forward price-to-earnings ratio of 14.57. The price/earnings-to-growth ratio is 4.53.

What is United Therapeutics's EPS forecast for next year?

United Therapeutics's earnings are expected to grow from $15.21 per share to $17.64 per share in the next year, which is a 15.98% increase.

More Earnings Resources from MarketBeat

Earnings Tools:
Earnings By Country:
Latest Articles:
Upcoming Earnings:
This page (NASDAQ:UTHR) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.